How to Achieve Reliable and Reproducible ELISA Results

ELISA (enzyme-linked immunosorbent assay) is one of the most widely used methods for quantifying analytes in biological samples. In addition to its high sensitivity and specificity, ELISA is valued for its relative simplicity and cost-effectiveness compared with many other analytical techniques. However, while the procedure may appear straightforward, accurate measurement of biological samples can involve important technical considerations.

How to Achieve Reliable and Reproducible ELISA Results

Concept of a Sandwich ELISA Assay

In a typical sandwich ELISA, a 96-well microtiter plate is pre-coated with a target-specific capture antibody, which may be monoclonal or polyclonal. The sample is then added to the wells and incubated, allowing the protein of interest to bind to the immobilized capture antibody.

Next, a detection antibody is added. This antibody binds to a separate site on the target antigen, forming an antibody–antigen–antibody complex: capture antibody–target antigen–detection antibody.

 

 

Quantification of the results is achieved by introducing an enzyme-conjugated antibody that binds specifically to the detection antibody, catalyzing a colorimetric enzymatic reaction. After a brief incubation with an appropriate substrate, the amount of enzyme conjugate bound in the well can be detected. The resulting color change in the well is then measurable using a standard microtiter plate ELISA reader, which records the absorbance (optical density). A higher signal indicates a higher concentration of the analyte in the sample, corresponding to the range established by the standard curve.

 

 

How to Achieve Reliable and Reproducible ELISA Results

 

To obtain reliable results it is recommended to choose an ELISA Assay that has gone through a full validation protocol. Results (validation data) must be provided that include data on specificity, sensitivity (LOD, LLOQ), accuracy/recovery, parallelism and dilution linearity, precision (within-run and in-between run), calibration, stability, and lot-to-lot consistency.

 

 

How to Achieve Reliable and Reproducible ELISA Results

 

 Key Elements of ELISA Assay Validation

 1. Specificity

Specificity ensures accurate measurement of the target protein or biomarker.The performance of an ELISA assay depends largely on the quality of the antibody pair used to detect the analyte of interest.

To achieve high specificity, the assay developer should:

-Select antibody pairs with high affinity and specificity, ideally with well-characterized binding sites.

-Optimize the ELISA kit to accurately quantify biomarkers in both healthy and disease-state samples.

2. Sensitivity

 Sensitivity describes an ELISA assay’s ability to detect very low concentrations of the target analyte.

In an ELISA, sensitivity is determined by the lowest amount of protein that can be detected using the antibody pair included in the kit. It depends largely on the affinity of the solid-phase, or coating, antibody. Using a higher-affinity antibody can therefore improve assay sensitivity.

-Analytical sensitivity / Limit of Detection (LOD): The lowest analyte concentration that can be detected with statistical significance using a specific analytical method. It is typically calculated as the background signal plus or minus two standard deviations.

-Functional sensitivity / Lower Limit of Quantification (LLOQ): The lowest analyte concentration that can be reliably detected and quantified.

3. Accuracy / Recovery

Accuracy evaluates whether an ELISA assay correctly detects the presence or absence of the target protein or antigen in different sample matrices, such as serum and plasma. It also helps identify potential matrix effects that could interfere with accurate measurement of the analyte.

Ideally, accuracy should be assessed in every sample type in which the analyte will be measured, including serum, EDTA plasma, and heparin plasma. To evaluate recovery, each matrix is spiked with known concentrations of recombinant analyte. The samples are then measured against the assay’s standard curve, and the observed concentrations are compared with the expected, or nominal, values.

4. Parallelism / Dilution Linearity

Parallelism and dilution linearity confirm that samples can be measured accurately and reliably across different dilution levels.

-Parallelism assesses whether samples containing high endogenous concentrations of the analyte produce results that remain consistent with the assay’s standard curve after serial dilution. This evaluation can reveal differences in antibody binding affinity between the endogenous analyte in real samples and the recombinant analyte used to calibrate the ELISA. Parallelism should always be evaluated during assay validation using samples with naturally occurring analyte levels.

-Dilution linearity evaluates analyte recovery in samples spiked with the recombinant analyte used to generate the assay standards. It determines whether measured concentrations remain proportional and accurate following serial dilution.

5. Precision

Precision assesses an ELISA assay’s ability to produce consistent and reliable results both within a single run and across different kit lots.

-Within-run precision (repeatability): Evaluates variation among multiple measurements of the same sample performed during a single assay run.

-Between-run precision: Evaluates the consistency of results when samples are tested repeatedly in separate assay runs, including runs performed with different ELISA kit lots. This confirms that the assay provides accurate and reproducible results over time and across lot-to-lot variations.

6. Calibration

Calibration enables accurate quantification of the target protein.

-Accurate measurement depends on the linearity and reproducibility of the assay’s standard curve. During ELISA kit optimization, variability among calibrator results should be minimized. When available, standards traceable to NIBSC or WHO reference materials should be used to support harmonized assay standardization.

7. Stability

Stability evaluates both the integrity of the target analyte in sample matrices and the stability of ELISA kit reagents.

During assay development, all assay components should be assessed for stability, along with the analyte in relevant sample types, such as serum and plasma.

-Analyte stability: This can be evaluated by exposing samples to repeated freeze–thaw cycles or storing them at room temperature for a defined period before analysis.

-Kit reagent stability: ELISA reagents should be tested under different temperature conditions for specified time periods to confirm their stability.

-Shelf-life: Real-time stability testing should be performed throughout the intended shelf-life of the kit. For example, reagents stored at 4°C may be evaluated after 6, 12, and 18 months.

8. Lot-to-Lot Consistency

Lot-to-lot consistency ensures that different ELISA kit batches provide comparable and reliable results.

-To assess consistency, each kit lot is tested using in-house control samples, including serum and plasma samples containing endogenous analyte as well as samples spiked with recombinant analyte. Results are evaluated to confirm that they fall within established quality-control ranges.

 

 

Achieving Reproducible ELISA Assay Results

BIOMEDICA ELISA kits undergo comprehensive validation in accordance with international quality guidelines. This helps ensure that your valuable samples are measured accurately and that the assay specifically detects the analyte of interest.

Learn more about achieving reproducible ELISA assay results on our website : QUALITY 

 

Why Choose BIOMEDICA ELISA Kits?

 

-Specific: Accurate biomarker detection using well-characterized antibodies.

-Reliable: Validated using clinical samples.

-Reproducible: Consistent performance across ELISA kit lots.

 

 

 

Further reading 

A Practical Guide to Immunoassay Method Validation.

Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB, Kulic L, Lewczuk P, Mollenhauer B, Mroczko B, Parnetti L, Vanmechelen E, Verbeek MM, Winblad B, Zetterberg H, Koel-Simmelink M, Teunissen CE.Front Neurol. 2015 Aug 19;6:179. doi: 10.3389/fneur.2015.00179. PMID: 26347708; PMCID: PMC4541289.